Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies

  • Monica M. Mita
  • , Alain C. Mita
  • , Jennifer L. Moseley
  • , Jennifer Poon
  • , Karen A. Small
  • , Ying Ming Jou
  • , Paul Kirschmeier
  • , Da Zhang
  • , Yali Zhu
  • , Paul Statkevich
  • , Kamelesh K. Sankhala
  • , John Sarantopoulos
  • , James M. Cleary
  • , Lucian R. Chirieac
  • , Scott J. Rodig
  • , Rajat Bannerji
  • , Geoffrey I. Shapiro

Research output: Contribution to journal › Article › peer-review

50 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science